RU2016131879A - Химерные белки, подобные щелочной фостофазе - Google Patents
Химерные белки, подобные щелочной фостофазе Download PDFInfo
- Publication number
- RU2016131879A RU2016131879A RU2016131879A RU2016131879A RU2016131879A RU 2016131879 A RU2016131879 A RU 2016131879A RU 2016131879 A RU2016131879 A RU 2016131879A RU 2016131879 A RU2016131879 A RU 2016131879A RU 2016131879 A RU2016131879 A RU 2016131879A
- Authority
- RU
- Russia
- Prior art keywords
- protein
- polynucleotide
- disease
- vector
- hypophosphatasia
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims 14
- 102000004169 proteins and genes Human genes 0.000 claims 14
- 108091033319 polynucleotide Proteins 0.000 claims 10
- 102000040430 polynucleotide Human genes 0.000 claims 10
- 239000002157 polynucleotide Substances 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 206010049933 Hypophosphatasia Diseases 0.000 claims 7
- 208000017169 kidney disease Diseases 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 210000003734 kidney Anatomy 0.000 claims 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- 206010048259 Zinc deficiency Diseases 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 208000015580 Increased body weight Diseases 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 201000009053 Neurodermatitis Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 201000008101 adult hypophosphatasia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 1
- 235000011180 diphosphates Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000037906 ischaemic injury Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 230000009984 peri-natal effect Effects 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03001—Alkaline phosphatase (3.1.3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Plant Pathology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
Claims (16)
1. Выделенный белок, имеющий фосфатазную активность, содержащий аминокислотную последовательность из по меньшей мере 200 последовательных аминокислот, имеющую по меньшей мере 90%-ную идентичность последовательности с SEQ ID NO: 5, аминокислотную последовательность из по меньшей мере 50 последовательных аминокислот, имеющую по меньшей мере 90%-ную идентичность последовательности с SEQ ID NO: 6, и аминокислотную последовательность из по меньшей мере 40 последовательных аминокислот, имеющую по меньшей мере 90%-ную идентичность последовательности с SEQ ID NO: 7, где полноразмерный белок содержит аминокислотную последовательность, имеющую по меньшей мере 90%-ную идентичность последовательности с полноразмерной аминокислотной последовательностью SEQ ID NO: 1, при условии, что аминокислота в положении 279 представляет собой лейцин (L), аминокислота в положении 328 представляет собой валин (V), и аминокислота в положении 478 представляет собой лейцин (L).
2. Полинуклеотид, содержащий нуклеиновокислотную последовательность, кодирующую белок по п. 1.
3. Вектор, содержащий полинуклеотид по п. 2.
4. Белок по п. 1, полинуклеотид по п. 2 или вектор по п. 3 для применения в качестве лекарственного средства.
5. Белок, полинуклеотид или вектор по п. 4 для предупреждения или лечения заболевания, сопровождающегося местной или системной недостаточностью цинка.
6. Белок, полинуклеотид или вектор для применения по п. 4 или 5 для предупреждения или лечения воспалительного заболевания, заболевания почки или гипофосфатазии.
7. Белок, полинуклеотид или вектор для применения по п. 6, где указанное воспалительное заболевание выбрано из группы, состоящей из аутоиммунных заболеваний, ревматоидного артрита, астмы, хронического обструктивного заболевания легких, атеросклероза, воспалительного заболевания желудочно-кишечного тракта, инфекции, сепсиса, нейродерматита, воспалительного заболевания печени, воспалительного заболевания легкого и воспалительного заболевания почки.
8. Белок, полинуклеотид или вектор для применения по п. 6, где указанное заболевание почки выбрано из группы, состоящей из повреждения почки, острого повреждения почки, хронического заболевания почки, почечной недостаточности, острой почечной недостаточности, ишемического заболевания почки и ишемического/реперфузионного повреждения почки.
9. Белок, полинуклеотид или вектор для применения по п. 6, где указанная гипофосфатазия выбрана из группы, состоящей из перинатальной гипофосфатазии, младенческой гипофосфатазии, детской гипофосфатазии и взрослой гипофосфатазии.
10. Клетка-хозяин, содержащая белок по п. 1, полинуклеотид по п. 2 или вектор по п. 3.
11. Клетка-хозяин по п. 10, представляющая собой клетку СНО (яичников китайского хомяка).
12. Способ получения белка по п. 1, включающий культивирование клетки-хозяина по п. 10 или п. 11 и обеспечение продуцирования клеткой-хозяином указанного белка.
13. Композиция, содержащая белок по п. 1 и/или получаемая способом по п. 12.
14. Композиция по п. 13 для применения в качестве лекарственного средства.
15. Композиция по п. 13 или 14 для применения в предупреждении или лечении заболевания, сопровождающегося местной или системной недостаточностью цинка, воспалительного заболевания, заболевания почки или гипофосфатазии.
16. Белок, полинуклеотид или вектор для применения по п. 6 или 9 или композиция для применения по п. 15, где указанное предупреждение или лечение гипофосфатазии приводит к продленному выживанию, повышенной массе тела, улучшенному скелетному фенотипу, ослаблению черепно-лицевых дефектов, улучшению зубочелюстного фенотипа и/или уменьшению плазматических уровней PPi (неорганический пирофосфат).
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14152526.1 | 2014-01-24 | ||
EP14152526 | 2014-01-24 | ||
EP14188158.1 | 2014-10-08 | ||
EP14188158 | 2014-10-08 | ||
PCT/NL2015/050048 WO2015112017A1 (en) | 2014-01-24 | 2015-01-26 | Chimeric alkaline phosphatase-like proteins |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2016131879A true RU2016131879A (ru) | 2018-03-01 |
RU2016131879A3 RU2016131879A3 (ru) | 2018-08-16 |
RU2683635C2 RU2683635C2 (ru) | 2019-03-29 |
Family
ID=52464544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016131879A RU2683635C2 (ru) | 2014-01-24 | 2015-01-26 | Химерные белки, подобные щелочной фосфатазе |
Country Status (22)
Country | Link |
---|---|
US (4) | US9926544B2 (ru) |
EP (2) | EP3425048A1 (ru) |
JP (3) | JP6940949B2 (ru) |
KR (1) | KR102166110B1 (ru) |
CN (2) | CN111778228A (ru) |
AU (1) | AU2015209783B2 (ru) |
BR (1) | BR112016017041B1 (ru) |
CA (1) | CA2937328C (ru) |
DK (1) | DK3097189T3 (ru) |
ES (1) | ES2684639T3 (ru) |
HU (1) | HUE039784T2 (ru) |
IL (1) | IL246898B (ru) |
MX (1) | MX369041B (ru) |
PE (1) | PE20161442A1 (ru) |
PH (1) | PH12016501441A1 (ru) |
PL (1) | PL3097189T3 (ru) |
RU (1) | RU2683635C2 (ru) |
SA (1) | SA516371532B1 (ru) |
SG (1) | SG11201606060WA (ru) |
SI (1) | SI3097189T1 (ru) |
WO (1) | WO2015112017A1 (ru) |
ZA (1) | ZA201605028B (ru) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111778228A (zh) | 2014-01-24 | 2020-10-16 | 安-法玛公司 | 嵌合型碱性磷酸酶样蛋白 |
WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
EP3226891A1 (en) | 2014-12-05 | 2017-10-11 | Alexion Pharmaceuticals, Inc. | Treating seizure with recombinant alkaline phosphatase |
JP6868561B2 (ja) | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | アルカリホスファターゼ欠損を有する被験者を治療する方法 |
KR102644116B1 (ko) | 2015-08-17 | 2024-03-05 | 알렉시온 파마슈티칼스, 인코포레이티드 | 알칼린 포스파타제의 제조 |
WO2017074466A1 (en) | 2015-10-30 | 2017-05-04 | Alexion Pharmaceuticals, Inc. | Methods for treating craniosynostosis in a patient |
US11065306B2 (en) | 2016-03-08 | 2021-07-20 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
JP2019513711A (ja) | 2016-04-01 | 2019-05-30 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | アルカリホスファターゼによって筋力低下を治療すること |
US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
EP3345614A1 (en) * | 2017-01-05 | 2018-07-11 | Amrif B.V. | Composition comprising alkaline phosphatase for use in the treatment of arthritides |
CN110719786A (zh) * | 2017-03-31 | 2020-01-21 | 阿雷克森制药公司 | 用于治疗成人和青少年的低磷酸酯酶症(hpp)的方法 |
US11338020B2 (en) | 2018-01-09 | 2022-05-24 | Synthetic Biologics, Inc. | Alkaline phosphatase agents for treatment of neurodevelopmental disorders |
EP4342534A3 (en) * | 2018-03-08 | 2024-05-22 | AM-Pharma B.V. | Recombinant alkaline phosphatase for use in treating sepsis-associated acute kidney injury |
WO2019183208A1 (en) | 2018-03-20 | 2019-09-26 | Synthetic Biologics, Inc. | Intestinal alkaline phosphatase formulations |
EP3773686B1 (en) | 2018-03-20 | 2023-06-07 | Theriva Biologics, Inc. | Alkaline phosphatase agents for treatment of radiation disorders |
WO2019190752A1 (en) | 2018-03-30 | 2019-10-03 | Alexion Pharmaceuticals, Inc. | Manufacturing of glycoproteins |
CN110499283A (zh) * | 2018-05-17 | 2019-11-26 | 西安组织工程与再生医学研究所 | Wnt信号通路激活剂在制备改善低碱性磷酸酯酶症干细胞成骨分化能力异常产品中的应用 |
CN111110835A (zh) * | 2020-01-22 | 2020-05-08 | 李鑫荣 | 一种肠碱性磷酸酶的新应用及其制剂的细胞活性检测方法 |
US20240009280A1 (en) | 2020-09-09 | 2024-01-11 | Am-Pharma B.V. | Recombinant alkaline phosphatase for use in treating acute respiratory distress syndrome |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8328918D0 (en) | 1983-10-28 | 1983-11-30 | Unilever Plc | Alkaline phosphatase |
ATE157702T1 (de) | 1990-02-07 | 1997-09-15 | Abbott Lab | Alkalische phosphatase mit verbesserter spezifischer aktivität zur verwendung in indikatorreagenzien |
ATE175998T1 (de) | 1992-03-10 | 1999-02-15 | Jolla Cancer Res Found | Rekombinierte alkalische phosphatase aus kälberdarm |
JPH06284885A (ja) * | 1993-04-02 | 1994-10-11 | Tosoh Corp | 組換えヒト小腸アルカリフォスファタ−ゼ |
AU698101B2 (en) | 1993-06-01 | 1998-10-22 | Cortex Pharmaceuticals, Inc. | Alkaline and acid phosphatase inhibitors in treatment of neurological disorders |
AU4835693A (en) | 1993-08-13 | 1995-03-14 | Rijksuniversiteit Te Groningen | Pharmaceutical composition comprising phosphatase or a derivative thereof |
DE69431527T2 (de) | 1993-11-15 | 2003-06-26 | Celtrix Pharma | Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung |
MXPA97009909A (es) | 1995-06-06 | 2004-08-23 | Gensci Regeneration Lab Inc | Materiales osteogenicos modificados. |
FR2736065B1 (fr) | 1995-06-29 | 1997-09-19 | Commissariat Energie Atomique | Phosphatases alcalines bacteriennes modifiees et leurs applications. |
JP3488327B2 (ja) | 1995-12-21 | 2004-01-19 | よつ葉乳業株式会社 | 牛乳脂肪球膜含有画分の製造法 |
US20020114802A1 (en) | 1998-02-10 | 2002-08-22 | Tjellstrom Bo Arthur Einar | Oral immunoglobulin treatment for inflammatory bowel disease |
DE19819962A1 (de) | 1998-05-05 | 1999-11-11 | Roche Diagnostics Gmbh | Hochaktive alkalische Phosphatase |
WO2000037943A1 (en) | 1998-12-21 | 2000-06-29 | Stichting Voor De Technische Wetenschappen | Diagnosis of sepsis using the lps-binding moiety of alkaline phosphatase |
JP2000350596A (ja) | 1999-06-11 | 2000-12-19 | Toyobo Co Ltd | 分泌性アルカリフォスファターゼの選択的活性測定方法 |
PT1132086E (pt) | 2000-01-31 | 2006-09-29 | Pfizer Prod Inc | Utilizacao de agonistas selectivos para o receptor da prostaglandina (pge2) 4 (ep4) para o tratamento de falha renal aguda e cronica |
EP1306367B1 (en) | 2000-07-19 | 2007-07-18 | Mitsubishi Pharma Corporation | Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products |
EP1191097A1 (en) | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
DE10101793A1 (de) | 2001-01-17 | 2002-08-01 | Manfred Nilius | Verwendung von SLPI zur Behandlung chronisch-entzündlicher Darmerkrankungen |
CA2434362A1 (en) | 2001-01-20 | 2002-07-25 | Cardion Ag | Pluripotent adult stem cells derived from regenerative tissue |
WO2002098433A1 (fr) | 2001-06-01 | 2002-12-12 | Ajinomoto Co., Inc. | Medicaments pour les maladies intestinales |
US7157260B2 (en) | 2001-07-26 | 2007-01-02 | Japan Science & Technology Agency | Nicotianamine synthase and gene encoding the same |
JP4169966B2 (ja) | 2001-11-14 | 2008-10-22 | 株式会社ヤクルト本社 | 炎症性腸疾患予防治療剤 |
CN1425766A (zh) | 2001-12-19 | 2003-06-25 | 复旦大学 | 一种多肽——人含碱性磷酸酶活性位点的蛋白-9.24和编码这种多肽的多核苷酸 |
EP1578940A4 (en) * | 2002-11-13 | 2007-12-12 | Genentech Inc | METHOD AND COMPOSITIONS FOR DYSPLASED DIAGNOSIS |
US7048914B2 (en) | 2002-12-12 | 2006-05-23 | Zoltan Laboratories | Placental alkaline phosphatase to control diabetes |
WO2004056987A1 (en) | 2002-12-23 | 2004-07-08 | Rijksuniversiteit Groningen | Modulation of the thioredoxin pathway |
AU2003225410A1 (en) | 2003-03-21 | 2004-10-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
JP4305071B2 (ja) | 2003-06-30 | 2009-07-29 | 株式会社ニコン | 信号補正方法 |
JP2005065564A (ja) | 2003-08-22 | 2005-03-17 | Hiroshi Ueda | センサー蛋白質 |
US7157261B2 (en) | 2003-10-27 | 2007-01-02 | Canji, Inc. | Rat secreted embryonic alkaline phosphatase |
US20110142817A1 (en) | 2004-02-04 | 2011-06-16 | Pharmaaware Sepsis B.V. | Means and method for treating and/or preventing necrotizing enterocolitis |
EP1713541B1 (en) | 2004-02-04 | 2017-03-22 | AM-Pharma B.V. | Use of alkaline phosphatase for the detoxification of lps |
CA2599577A1 (en) | 2005-03-04 | 2006-09-14 | Verenium Corporation | Nucleic acids and proteins and methods for making and using them |
US20070059300A1 (en) | 2005-09-12 | 2007-03-15 | Zoltan Laboratories Llc | Compounds and compositions to control abnormal cell growth |
WO2007075199A1 (en) | 2005-12-28 | 2007-07-05 | Zoltan Laboratories Llc | Use of alkaline phosphatase to maintain healthy tissue mass in mammals |
RU2006103770A (ru) * | 2006-02-08 | 2007-08-20 | Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран) (Ru) | Высокоактивная бактериальная щелочная фосфатаза и фрагмент днк, кодирующий щелочную фосфатазу |
US20070280922A1 (en) | 2006-06-06 | 2007-12-06 | Zoltan Kiss Consulting | Combinations of human proteins to enhance viability of stem cells and progenitor cells |
US7718170B2 (en) | 2006-08-21 | 2010-05-18 | Essential Skincare, Llc | Alkaline phosphatase compositions to reduce skin cancer |
EP1952823A1 (en) | 2007-01-30 | 2008-08-06 | AM-Pharma B.V. | The use of alkaline phosphatase in the treatment of reduced renal function |
WO2008104199A1 (en) | 2007-03-01 | 2008-09-04 | Gelato Corporation N.V. | Use of ecto-phosphatases for the treatment of (acute) myocardial infarction |
EP1985697A1 (en) | 2007-04-27 | 2008-10-29 | AM-Pharma B.V. | Modified phosphatases |
ATE536413T1 (de) * | 2007-05-11 | 2011-12-15 | Enobia Pharma Inc | Auf knochen als ziel gerichtete alkalische phosphatase, kits und verwendungsverfahren dafür |
EP2030980A1 (en) | 2007-08-28 | 2009-03-04 | AM-Pharma B.V. | Mutants of lactoferrin |
WO2009106368A1 (en) | 2008-02-29 | 2009-09-03 | Gelato Corporation N.V. | Method for increasing the activity of the immune system of a mammal at risk of inflammatory diseases |
CA2723424A1 (en) | 2008-05-19 | 2009-11-26 | Burnham Institute For Medical Research | Intestinal alkaline phosphatase modulators and uses thereof |
AU2009285725A1 (en) | 2008-08-29 | 2010-03-04 | The General Hospital Corporation | Methods of modulating gastrointestinal tract flora levels with alkaline phosphatase |
JP5986986B2 (ja) * | 2010-04-30 | 2016-09-06 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 基質石灰化障害を治療する方法、組成物、およびキット |
DK3222286T3 (da) | 2011-06-08 | 2020-11-09 | Am Pharma Bv | Anvendelse af alkalisk phosphatase til bevaring af nyrefunktion |
JP6713147B2 (ja) | 2014-01-24 | 2020-06-24 | アーエム−ファルマ ベー.フェー.AM−Pharma B.V. | アルカリホスファターゼの下流プロセシング |
CN111778228A (zh) | 2014-01-24 | 2020-10-16 | 安-法玛公司 | 嵌合型碱性磷酸酶样蛋白 |
-
2015
- 2015-01-26 CN CN202010673719.7A patent/CN111778228A/zh active Pending
- 2015-01-26 DK DK15703642.7T patent/DK3097189T3/en active
- 2015-01-26 PE PE2016001271A patent/PE20161442A1/es unknown
- 2015-01-26 EP EP18174759.3A patent/EP3425048A1/en not_active Withdrawn
- 2015-01-26 US US15/113,696 patent/US9926544B2/en active Active
- 2015-01-26 EP EP15703642.7A patent/EP3097189B1/en active Active
- 2015-01-26 CA CA2937328A patent/CA2937328C/en active Active
- 2015-01-26 ES ES15703642.7T patent/ES2684639T3/es active Active
- 2015-01-26 WO PCT/NL2015/050048 patent/WO2015112017A1/en active Application Filing
- 2015-01-26 CN CN201580016357.1A patent/CN106164262B/zh active Active
- 2015-01-26 SI SI201530345T patent/SI3097189T1/sl unknown
- 2015-01-26 PL PL15703642T patent/PL3097189T3/pl unknown
- 2015-01-26 HU HUE15703642A patent/HUE039784T2/hu unknown
- 2015-01-26 BR BR112016017041-5A patent/BR112016017041B1/pt active IP Right Grant
- 2015-01-26 RU RU2016131879A patent/RU2683635C2/ru active
- 2015-01-26 SG SG11201606060WA patent/SG11201606060WA/en unknown
- 2015-01-26 JP JP2016548124A patent/JP6940949B2/ja active Active
- 2015-01-26 MX MX2016009625A patent/MX369041B/es active IP Right Grant
- 2015-01-26 AU AU2015209783A patent/AU2015209783B2/en active Active
- 2015-01-26 KR KR1020167022726A patent/KR102166110B1/ko active IP Right Grant
-
2016
- 2016-07-19 ZA ZA2016/05028A patent/ZA201605028B/en unknown
- 2016-07-20 PH PH12016501441A patent/PH12016501441A1/en unknown
- 2016-07-21 IL IL246898A patent/IL246898B/en active IP Right Grant
- 2016-07-21 SA SA516371532A patent/SA516371532B1/ar unknown
-
2018
- 2018-02-07 US US15/891,208 patent/US10822597B2/en active Active
-
2019
- 2019-12-20 JP JP2019230887A patent/JP2020058375A/ja active Pending
-
2020
- 2020-10-16 US US17/072,893 patent/US11746340B2/en active Active
-
2022
- 2022-07-22 JP JP2022117484A patent/JP7408734B2/ja active Active
-
2023
- 2023-05-30 US US18/325,714 patent/US20240174994A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2016131879A (ru) | Химерные белки, подобные щелочной фостофазе | |
WO2014202616A3 (en) | Rasamsonia gene and use thereof | |
JP2017511148A5 (ru) | ||
JP2016073298A5 (ru) | ||
WO2014118360A3 (en) | Carbohydrate degrading polypeptide and uses thereof | |
EA201890220A1 (ru) | Вакцина против rsv | |
JP2011155981A5 (ru) | ||
JP2016034981A5 (ru) | ||
RU2018108836A (ru) | ВАРИАНТЫ Fc И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
RU2018112989A (ru) | Кислотная композиция, содержащая фикоцианин | |
Suwal et al. | Recovery of valuable peptides from marine protein hydrolysate by electrodialysis with ultrafiltration membrane: impact of ionic strength | |
WO2016183438A8 (en) | Self-targeting genome editing system | |
JP2014531205A5 (ru) | ||
JP2018531624A5 (ru) | ||
EA201201126A1 (ru) | Полипептид, обладающий активностью целлобиогидролазы, и его применение | |
WO2014202622A3 (en) | Rasamsonia gene and use thereof | |
BR112014017919A2 (pt) | uso de um poliptídeo variante, composição, polinucleotídeo isolado, constructo de ácido nucleico ou vetor de expressão, célula hospedeira de expressão recombinante, métodos de produção do pilipeptídeo, para melhoria do valor nutricional de uma ração animal, e para o tratamento de proteínas, planta, parte de planta ou célula de planta transgênica, aditivo de ração animal, ração animal, e, composição de ração animal ou detergente | |
WO2015160853A3 (en) | Antibody therapeutics that bind cd147 | |
RU2017122972A (ru) | Способ избирательной флотации каинита из минеральных смесей с использованием сульфатированных жирных кислот в качестве коллектора | |
BR112015002484A2 (pt) | xilanases para solubilização de material contendo arabinoxilano | |
HRP20170541T1 (hr) | Željezni (iii) kazeinsukcinilat i postupak njegovog dobivanja | |
MX2019002134A (es) | Nuevo paramixovirus y sus usos. | |
WO2016022958A3 (en) | Tick-associated virus sequences and uses thereof | |
EP4209504A8 (en) | Process for preparing apolipoprotein a-i (apo a-i) | |
WO2014057437A3 (fr) | Procede de preparation de proteine c1q recombinante |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC9A | Changing information about inventors | ||
PD4A | Correction of name of patent owner |